In vitro application of the CHK1 inhibitor prexasertib to SCLC cells revealed an increase in cytosolic DNA and activation of the cGAS-STING-TBK1 signaling pathway, a significant increase in PD-L1 expression, and suppression of tumor immune escape. This evidence concerns the gene CHEK1 and small cell lung carcinoma.